Portfolio companies news

04 April 2017

ReVision Optics Celebrates 1,000 Raindrop Near Vision Inlay Procedures Improving Near Vision for Individuals with Presbyopia

ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces that 1,000 Raindrop® Near Vision Inlay procedures have been performed since the company’s commercial launch of the product in late August 2016. The Raindrop Near Vision Inlay is a novel corneal inlay for the surgical correction of presbyopia, which is a natural part of the aging process that decreases the ability of the eye to focus on near objects.

04 April 2017

OCON Medical launches IUD in Europe

Gali Weinreb / Globes

OCON Medical, which is developing an intrauterine device (IUD) in a new configuration, has launched its product in Spain and Belgium. OCON Medical founder Dr. Ilan Baram told "Globes" that sales of the product had already topped $1 million in eight countries. In Israel, pharma company Perrigo Company (NYSE:PRGO; TASE:PRGO) has been distributing the product since last August.

31 March 2017

Clearside Biomedical Enters into Strategic Collaboration with EyeKor to Support Clinical Development Efforts

Clearside Biomedical Inc.  (Nasdaq:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that it has entered into a strategic collaboration with  EyeKor Inc.  to support Clearside’s ophthalmic clinical trial activities. 

23 March 2017

Neothetics Provides Business Update and Reports Fourth Quarter 2016 Financial Results

Neothetics, Inc. (NASDAQ:NEOT) today provided a business update and reported financial results for the fourth quarter 2016. “We are encouraged by our progress on our Phase 2 proof of concept trial for LIPO-202 in submental fat reduction and continue to expect top-line data in June 2017,” said Mr. Jeffrey M. Nugent, a member of Neothetics’ Operating Committee and Board of Directors.

20 March 2017

Neothetics Announces Last Subject Enrolled in Phase 2 Proof of Concept Trial for LIPO-202 for the Reduction of Submental Subcutaneous Fat

Neothetics, Inc. (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today announced completion of subject enrollment for its Phase 2 proof of concept trial, LIPO-202-CL-31, for the reduction of submental subcutaneous fat.  

17 March 2017

Miramar Labs, Inc.® Reports Fourth Quarter and Full Year 2016 Financial Results

Miramar Labs, Inc., (OTCQB:MRLB), a global aesthetic company, announced today financial results for fourth quarter and full year ended December 31, 2016. 2016 revenue of $20.4 million, up 19% year-over-year. Strong sales in North America with year-over-year growth of 38%. Gross margin expands to 55% in 2016, up from 52% in the prior year.

14 March 2017

Clearside Biomedical, Inc. Announces Fourth Quarter And Full Year 2016 Financial Results

Clearside Biomedical, Inc.  (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today reported financial results for the fourth quarter and full year ended  December 31, 2016 , and provided an update on its development programs.

13 March 2017

Marinus Pharmaceuticals Provides Business Update and 2016 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the year ended December 31, 2016.

02 March 2017

Syndax Pharmaceuticals Reports Fourth Quarter and Year-end 2016 Financial Results and Provides Clinical and Business Update

Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today reported its financial results for the fourth quarter and year ended December 31, 2016. In addition, the Company provided a pipeline update as well as a review of upcoming milestones. As of December 31, 2016, Syndax had $105.3 million in cash, cash equivalents and short-term investments.

28 February 2017

Clearside Biomedical, Inc. Receives Notice of Allowance for Ninth U.S. Patent

Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Number 15/001,610 entitled, “Methods and Devices for the Treatment of Ocular Diseases in Human Subjects.”